Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 10(65), 2021

DOI: 10.1128/aac.00443-21

Links

Tools

Export citation

Search in Google Scholar

Irritable Bowel Syndrome Therapeutic Has Broad-Spectrum Antimicrobial Activity

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Orange circle
Published version: archiving restricted
Data provided by SHERPA/RoMEO

Abstract

Otilonium bromide is a poorly absorbed oral medication used to control irritable bowel syndrome. It is thought to act as a muscle relaxant in the intestine. Here, we show that otilonium bromide has broad-spectrum antibacterial and antifungal activity, including against multidrug-resistant strains. Our results suggest otilonium bromide acts on enteric pathogens and may offer a new scaffold for poorly absorbed intestinal antimicrobial therapy.